ReviewClinical & developmental immunology2010
Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.
Review in Clinical & developmental immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03664869 (Intravesical Instillation Therapy With Bacillus Calmette-Guérin), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma
Who cites it
29 citing papers in PubMed, 54 citations in OpenAlex.
- The significance of trained immunity in cancer.Frontiers in immunology · 2025Review
- Revitalizing Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches.Pharmaceutics · 2024Review
- Efficacy of Bacillus Calmette-Guérin in Cancer Prevention and Its Putative Mechanisms.Journal of cancer prevention · 2024Review
- The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer.International journal of molecular sciences · 2024Review
- The Urinary Microbiome: Role in Bladder Cancer and Treatment.Diagnostics (Basel, Switzerland) · 2022Review
- Intravesical Pseudomonas aeruginosa mannose-sensitive Hemagglutinin vaccine triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model.Cancer immunology, immunotherapy : CII · 2022Article
- Novel molecules as the emerging trends in cancer treatment: an update.Medical oncology (Northwood, London, England) · 2022Review
- Innate immune memory is associated with increased disease-free survival in bladder cancer patients treated with bacillus Calmette-Guérin.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Article
- Zinc transporter SLC39A7 relieves zinc deficiency to suppress alternative macrophage activation and impairment of phagocytosis.PloS one · 2020Article
- The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice.Journal of translational medicine · 2019Article
- The multifaceted immune regulation of bladder cancer.Nature reviews. Urology · 2019Review
- Yeast-Derived β-Glucan in Cancer: Novel Uses of a Traditional Therapeutic.International journal of molecular sciences · 2019Review
- Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.Thyroid : official journal of the American Thyroid Association · 2019Article
- Mechanisms of BCG immunotherapy and its outlook for bladder cancer.Nature reviews. Urology · 2018Review
- Biocompatibility of Multi-Imaging Engineered Mesoporous Silica Nanoparticles:Journal of biomedical nanotechnology · 2017Article
- Defining Genome-Wide Expression and Phenotypic Contextual Cues in Macrophages Generated by Granulocyte/Macrophage Colony-Stimulating Factor, Macrophage Colony-Stimulating Factor, and Heat-Killed Mycobacteria.Frontiers in immunology · 2017Article
- Targeting tumor-associated macrophages to combat pancreatic cancer.Oncotarget · 2016Review
- Tumor-associated macrophages and anti-tumor therapies: complex links.Cellular and molecular life sciences : CMLS · 2016Review
- Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.Molecular cancer therapeutics · 2015Article
- NMAAP1 Expressed in BCG-Activated Macrophage Promotes M1 Macrophage Polarization.Molecules and cells · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many details of the molecular and cellular mechanisms involved in Mycobacterium bovis bacillus Calmette-Guérin (BCG) immunotherapy of bladder cancer have been discovered in the past decades. However, information on a potential role for macrophage cytotoxicity as an effector mechanism is limited. Macrophages play pivotal roles in the host innate immunity and serve as a first line of defense in mycobacterial infection. In addition to their function as professional antigen-presenting cells, the tumoricidal activity of macrophages has also been studied with considerable interest. Studies have shown that activated macrophages are potent in killing malignant cells of various tissue origins. This review summarizes the current understanding of the BCG-induced macrophage cytotoxicity toward bladder cancer cells with an intention to inspire investigation on this important but underdeveloped research field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.